Showing results (81-90 of 1,066) with videos related to
Sort By:
Pageof 107
Journal of Affective Disorders|March 3, 2012
The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramineP Bech, K B Stage, J K Larsen, et al.Therapeutic Drug Monitoring|January 1, 1982
Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressantsL F Gram, O L Pedersen, C B Kristensen, et al.Psychopharmacology|January 1, 1985
Orthostatic side effects of clomipramine and citalopram during treatment for depressionP Christensen, H Y Thomsen, O L Pedersen, et al.Acta Psychiatrica Scandinavica|March 1, 1975
Quantitative rating of depressive statesP Bech, L F Gram, E Dein, et al.European Journal of Clinical Pharmacology|January 1, 1996
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetineU Jeppesen, L F Gram, K Vistisen, et al.Journal of Internal Medicine|January 1, 1991
Drugs and femoral neck fracture: a case-control studyJ Jensen, L H Nielsen, N Lyhne, et al.International Clinical Psychopharmacology|January 1, 1994
Effects of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjectsA Patat, L F Gram, C Dubruc, et al.Neurology|April 23, 2003
Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trialS H Sindrup, F W Bach, C Madsen, et al.Psychopharmacology|January 1, 1982
Citalopram, a selective serotonin reuptake inhibitor: clinical antidepressive and long-term effect--a phase II studyO L Pedersen, P Kragh-Sørensen, M Bjerre, et al.European Journal of Clinical Pharmacology|January 1, 1993
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteineK Brøsen, J G Hansen, K K Nielsen, et al.Pageof 107